

Fibrosis Assessment in Children with  
Chronic Liver Disease

**Thesis**

*Submitted For Partial Fulfillment of  
Master Degree in Pediatrics*

**By**

Abdel Aziz Hassan Abdel Wanis

*M.B.,B.Ch*

**Supervised By**

Prof. Dr. Tawhida Yassin Abdel Ghaffar

*Professor of Pediatrics*

*Faculty of Medicine, Ain Shams University*

Prof. Dr. Gamal El-Din Essmat Mohammed

*Professor of Tropical medicine & Hepatology*

*Faculty of Medicine, Cairo University*

Dr. Azza Mohammed Youssef

*Assistant professor of Pediatrics*

*Faculty of Medicine, Ain Shams University*

Faculty of Medicine

Ain Shams University

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قالوا

لسببائك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



## Acknowledgement

*All praise is to Allah and all thanks. He has guided and enabled me by his mercy to fulfill this thesis, which I hope to be beneficial for people.*

*I would like to express my deepest gratitude and sincere appreciation to Prof. Dr. Tawhida Yassin Abdel Ghaffar, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her continuous encouragement, her kind support and appreciated suggestions that guided me to accomplish this work.*

*My greatest thanks go to Prof. Dr. Gamal El-Din Esmat Mohammed, Professor of Tropical Medicine, Cairo University, for his kindness and support, for allowing me to use freely all the facilities in his department, for his continuous help and creative discussions.*

*I am also deeply grateful and would like to express my sincere thanks and gratitude to Dr. Azza Mohammed Youssef, Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, support and her continuous guidance, correction and explanation.*

*Special thanks are extended to Prof. Dr.Khalid RefaatZalata, Professor of Pathology, Mansoura University for his great help and support to accomplish this work.*

*I would like to thank, Dr.Ahmed Shadeed, Lecturer of Pediatrics, Ain Shams University for his help and support throughout the work.*

*I would like to express my profound gratitude to Dr.Aisha Mohammed Elsharkawy, Lecturer of Tropical medicine, Cairo University, for hersupport and unlimited help during this work.*

*My special thanks to all members in pediatric hepatology clinic, Ain Shams University, and to every one in Yassin Abdel Ghaffar Charity Center for Liver Diseases and Research. I would like to thank every child and his/her family in this thesis and I wish to be in a good health.*

*No words could adequately express my deep appreciation to my family; Mother,My brothers andSistersfor their continuous support and guidance. Finally I dedicate this workto the soul ofmy father who I couldn't forget him. And i should remain indebted to them all my life.*

 Abdel Aziz Hassan Abdel Wanis

2013

## Contents

Subjects	Page
• List of abbreviations.....	I
• List of Tables.....	IV
• List of Figures.....	IX
• Introduction.....	1
• Aim of the work.....	5
• Review of literature	
* <b>Chapter (1): Liver fibrosis</b> .....	6
–Definition.....	6
–Patterns of fibrosis progression.....	8
–Composition of the extracellular matrix of liver.....	9
–Mechanisms of extracellular matrix accumulation and degradation.....	11
– Biological activity of ECM in cell–matrix interactions.....	13
–Cellular sources of extracellular matrix in the liver.....	16
–Role of Other Resident Cells in Liver Fibrosis.....	21
–Cytokines and chemokines in fibrosis.....	23
–General mechanisms regulating hepatic fibrosis.....	31
–Disease specific mechanisms regulating hepatic fibrosis.....	34

---

–Progression and regression of fibrosis in chronic liver diseases.....	42
–Determinants of fibrosis progression.....	43
–Reversibility of fibrosis and cirrhosis.....	45
–Mechanisms regulating fibrosis resolution.....	46
–New therapeutic directions in hepatic fibrosis.....	47
<b>* Chapter (2): Assessment of fibrosis.....</b>	<b>50</b>
–Invasive assessment of liver fibrosis.....	50
–Non invasive assessment of liver fibrosis.....	55
–Imaging methods.....	75
<b>* Chapter (3): Transient Elastography (Fibroscan)....</b>	<b>79</b>
–Definition.....	79
–Principle.....	79
–Technique.....	80
–Interpretation of results.....	81
–Limitations.....	82
–Reproducibility.....	83
–Normal values of fibroscan.....	84
–Fibroscan in patients with acute hepatitis.....	85
–Fibroscan for assessment of fibrosis and its severity in different chronic liver diseases.....	86
–Fibroscan in chronic hepatitis c virus infection.....	88
–Fibroscan in HIV-HCV coinfection.....	90

---

–Fibroscan in hepatitis B infection .....	91
–Fibroscan in HCV recurrence after liver transplantation. .....	92
–Fibroscan in children.....	93
–Fibroscan and cholestatic liver diseases.....	94
–Fibroscan and non alcoholic fatty liver disease.....	95
–Fibroscan and esophageal varices.....	95
–Fibroscan in diagnosis of cirrhosis .....	97
–Comparison of Transient Elastography with serum markers.....	97
• Patients and Methods .....	101
• Results .....	113
• Discussion.....	142
• Summary and Conclusion .....	158
• Recommendations.....	167
• References.....	169
• Arabic summary.	

---

## *List of Abbreviations*

%	:	Percent.
-Ve	:	Negative.
+Ve	:	Positive.
ADAM	:	Adisintegrin and metalloproteinase domain molecules.
AIH	:	Autoimmune hepatitis.
ALD	:	Alcoholic liver disease.
ALK Ph	:	Alkaline phosphatase.
ALT	:	Alanine aminotransferase.
AMAs	:	Anti mitochondrial antibodies.
A-mode	:	Amplitude mode.
AMP	:	Adenosine monophosphate.
ANAs	:	Antinuclear antibodies.
Anti HCV	:	: Antibodies to hepatitis C virus.
ARFI	:	Acoustic radiation force impulse imaging.
AST	:	Aspartate aminotransferase.
AUROC	:	Area under receiver operating characteristic curve.
BCL-2	:	B Cell lymphoma-2.
BMI	:	Body mass index.
CF	:	Colony-stimulating factor.

---

---

 *List of Abbreviations* 

---

CHF	:	Congenital hepatic fibrosis.
CLDs	:	Chronic liver diseases.
CTGF	:	Connective tissue growth factor.
DDR-2	:	Discoidin domain receptor-2.
ECM	:	Extracellular matrix.
EMT	:	Epithelial to mesenchymal transition.
FFA	:	Free fatty acid.
GGT	:	Gamma glutamyl transferase.
GSD	:	Glycogen storage disease.
HA	:	Hyaluronic acid.
HBsAg	:	Hepatitis B surface antigen.
HBV	:	Hepatitis B virus.
HCC	:	Hepatocellular carcinoma.
HCV	:	Hepatitis C virus.
HGF	:	Hepatocyte growth factor.
INR	:	International normalized ratio.
MCP-1	:	Monocyte chemotactic protein1.
MIP-2	:	Macrophage inflammatory protein2.
PAF	:	Platelet activating factor;
PGF	:	Prostaglandin F.

---

---

 *List of Abbreviations* 

---

PPV	:	Positive predictive value.
PSC	:	Primary sclerosing cholangitis.
ROS	:	Reactive oxidative stress.
RBP4	:	Retinol binding protein 4.
SAFE	:	Sequential algorism for fibrosis evaluation.
SD	:	Standard deviation.
SECs	:	Sinusoidal endothelial cells.
SF	:	scatter factor.
Smad3	:	Mothers against DPP homolog 3.
SPSS	:	Statistical package for the social sciences.
STAT	:	Signal transducer and activator of transcription.
TE	:	Transient elastography.
TGF-b	:	Transforming growth factor-b.
TIMP	:	Tissue inhibitors of metalloproteinase.
TLRs	:	Toll like receptors.
T-mode	:	Tissue median mode.
TNF-a	:	Tumor necrosis factor –a.
ULN	:	Upper limit of normal.
Upa	:	Uroplasminogen activator.
VEGF	:	Vascular endothelial growth factor.
VLDL	:	Very low density lipoprotein.

---

## *List of Tables*

<b>Table No.</b>	<b>Title</b>	<b>page</b>
<b>Table (1)</b>	The different cut-off values of liver stiffness in different liver diseases.	88
<b>Table (2)</b>	TE cut-off values for the diagnosis of METAVIR fibrosis score.	90
<b>Table (3)</b>	The METAVIR group scoring system for fibrosis stages.	111
<b>Table (4)</b>	The ISHAK Modified Histological Staging System.	111
<b>Table (5)</b>	Descriptive data of studied children as regards aetiology of liver disease.	113
<b>Table (6)</b>	Age, Weight, Height and BMI of studied patients.	114
<b>Table (7)</b>	Sex distribution of studied patients.	114
<b>Table (8)</b>	Age, Weight, Height and BMI of control group.	115
<b>Table (9)</b>	Sex distribution of control group.	116
<b>Table (10)</b>	Comparison between Age, Wt. and BMI of patients and controls	116
<b>Table (11)</b>	Comparison between height distribution of diseased and control groups.	117

---

<b>Table No.</b>	<b>Title</b>	<b>page</b>
<b>Table (12)</b>	Comparison between sex distribution of the diseased and control groups.	118
<b>Table (13)</b>	Comparison between patients and controls in different age categories.	119
<b>Table (14)</b>	Descriptive data of studied patients as regards clinical data at time of the study.	119
<b>Table (15)</b>	Descriptive data of studied children as regards laboratory finding.	120
<b>Table (16)</b>	Descriptive data of studied children as regards Auto- Antibodies, viral markers and mutation analysis.	121
<b>Table (17)</b>	Studied children as regards abdominal duplex ultrasonography.	121
<b>Table (18)</b>	Liver biopsy examination assessed by both METAVIR and ISHAK score for the studied patients.	122
<b>Table (19)</b>	Liver stiffness measurement (LSM) by Fibroscan for the studied patients.	124
<b>Table (20)</b>	Liver stiffness measurement (LSM) by Fibroscan for the control group.	124
<b>Table (21)</b>	Comparison between liver stiffness measurement (LSM) of diseased and control groups.	125

---

<b>Table No.</b>	<b>Title</b>	<b>page</b>
<b>Table (22)</b>	Comparison between LSM by fibroscan in patients with fibrosis stage (<F2) and ( $\geq$ F2) by METAVIR of studied patients.	126
<b>Table (23)</b>	LSM by fibroscan and liver biopsy as assessed by METAVIR scoring system for different etiologies of liver disease other than WD and AIH of the studied patients	127
<b>Table (24)</b>	APRI score of the studied patients.	127
<b>Table (25)</b>	Comparison between cut off value of APRI score in patients with fibrosis stage (<F2) and ( $\geq$ F2) by METAVIR of studied patients.	128
<b>Table (26)</b>	Correlation between ISHAK score of liver biopsy and each (Metavir score, LSM and APRI score) in diseased group.	128
<b>Table (27)</b>	Correlation between Metavir score of liver biopsy and each (LSM by fibroscan and APRI score) in the studied patients.	129
<b>Table (28)</b>	Correlation between LSM by fibroscan and each (APRI score and platelets count) in the studied patients.	131

---

<b>Table No.</b>	<b>Title</b>	<b>page</b>
<b>Table (29)</b>	Correlation between ISHAK score of liver biopsy and each of (Metavir score by liver biopsy, LSM by fibroscan and APRI score) in Wilson patients.	132
<b>Table (30)</b>	Correlation between Metavir score of liver biopsy and each (LSM by fibroscan and APRI score) in the Wilson patients.	132
<b>Table (31)</b>	Correlation between LSM by fibroscan and APRI score in Wilson patients.	133
<b>Table (32)</b>	Correlation between ISHAK score of liver biopsy and each (Metavir score, LSM and APRI score) in AIH patients.	133
<b>Table (33)</b>	Correlation between Metavir score of liver biopsy and each (LSM by fibroscan and APRI score) in the AIH patients.	134
<b>Table (34)</b>	Correlation between LSM by fibroscan and APRI score in AIH patients.	134
<b>Table (35)</b>	ROC Curve of LSM in all studied patients.	135
<b>Table (36)</b>	ROC Curve of LSM in wilson patients.	136
<b>Table (37)</b>	ROC Curve of APRI score in all studied patients.	138
<b>Table (38)</b>	ROC Curve of APRI score in wilson patients.	139

---

---

 *List of Tables*

---

<b>Table No.</b>	<b>Title</b>	<b>page</b>
<b>Table (39)</b>	Logistic regression using both LSM and APRI score for prediction of liver fibrosis.	141
<b>Table (40)</b>	Logistic regression to predict liver fibrosis using APRI score and LSM (kpas).	141

---